Relative Reinforcing Strength of ThreeN-Methyl-d-Aspartate Antagonists with Different Onsets of Action
- Departments of 1Pharmacology and Psychology (G.W., J.H.W.) and2Physiology and Neurology (K.L.C.), University of Michigan, Ann Arbor, Michigan; 3Science Applications International (S.R.H.), Joppa, Maryland; and 4Johns Hopkins University School of Medicine (S.R.H.), Baltimore, Maryland
- Dr. Gail Winger, Department of Pharmacology, University of Michigan Medical School, 1301 MSRB III, Ann Arbor, MI 48109-0632. E-mail:gwinger{at}umich.edu
Abstract
The potential contribution of onset and duration of pharmacological action to the reinforcing strength of three intravenously deliveredN-methyl-d-aspartate antagonists was evaluated in this study. The onsets and durations of action of ketamine, phencyclidine, and dizocilpine were evaluated by observation and tabulation of their behavioral effects in rhesus monkeys after i.v. administration. The reinforcing effects of each drug were tested in a paradigm in which the fixed ratio requirements for i.v. drug injection were increased systematically. The peak observable effect of ketamine occurred immediately after its administration. There were some immediately observable effects of phencyclidine, although the peak effect of phencyclidine was delayed for 3 to 10 min. Dizocilpine had few immediate effects and a peak effect 32 min after administration. Ketamine had the shortest duration of action, followed by phencyclidine and dizocilpine. Analysis of demand curves and response output curves that were normalized to account for potency differences among the drugs revealed that ketamine and phencyclidine were equally effective as reinforcers, and they were both much stronger reinforcers than was dizocilpine. The data therefore suggest that a fast onset of action increases the reinforcing strength of drugs, although duration of action may play a role as well.
Footnotes
-
This research was supported by U.S. Public Health Service Grant DA-09161.
- Abbreviations:
- NMDA
- N-methyl-d-aspartate
- MK-801
- (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate
-
- Received October 9, 2001.
- Accepted February 6, 2002.
- The American Society for Pharmacology and Experimental Therapeutics



